MEDS4MAMA: optimisation of medication in pregnancy

he project aims to identify therapy disruptions using Swiss health insurance data and assess the impact of a digital tool (MAMA-MEDS) to improve medication use during pregnancy using evidence-based information.

Project description

The project addresses the critical gap in managing chronic diseases during pregnancy, focusing on optimising medication use to ensure maternal and foetal health. Despite the importance of treatment continuity, many pregnant women face therapy disruptions due to overestimated risks. In synergy with MAMA-MEDS, a digital platform offering evidence-based drug safety information, a randomised trial will evaluate the platform’s impact on reducing disruptions and improving decision-making.

Research aim

The aim of the project is to enhance safe and effective medication use during pregnancy. By analysing Swiss health data, we identify treatment disruptions for chronic diseases like asthma, diabetes and MS. In collaboration with a digital platform offering evidence-based drug safety in-formation, the project empowers healthcare providers and pregnant women to make informed de-cisions. It seeks to improve health outcomes by promoting evidence-based care and reducing un-necessary therapy changes.

Purpose

The project addresses a critical gap in pregnancy care, where fear and lack of evidence lead to unnecessary treatment changes, risking maternal and foetal health. By providing evidence-based medication guidance, it aims to empower informed decisions, improve health outcomes and ensure equitable access to safe, effective treatments. It also lays a foundation for better use of Swiss health data, advancing public health research and clinical practice for pregnant women with chronic conditions.